The Global Health Limited IPO GMP will begin on November 3, 2022, and end on November 7, 2022. The bid period for the Global Health IPO is from November 3, 2022, at 10:00 A.M. to November 7, 2022, at 5:00 P.M. The initial public offering (IPO) will include an offer-for-sale (OFS) of up to 5.08 crore equity shares as well as a fresh issue of equity shares totaling Rs 500 crore.
Global Health Limited IPO GMP
On November 3, Global Health, the company that owns the Medanta hospital chain, will begin a three-day share sale for public subscription (IPO). According to the red herring prospectus, the IPO will end on November 7. (RHP).
According to reports cited by news organisation Press Trust of India, the Global Health Limited IPO GMP size could be about Rs 2,200 crore. Anant Investments, a subsidiary of the large private equity firm Carlyle Group, and Sunil Sachdeva (together with Suman Sachdeva) will sell equity interests as part of the OFS.
Global Health Limited IPO GMP Dates
IPO Date | Nov 3, 2022 to Nov 7, 2022 |
Face Value | Rs. 2 per share |
Price | To be Announced |
Lot Size | To be Announced |
Issue Size | To be Announced |
Fresh Issue | aggregating up to ₹500.00 Cr |
Issue Type | Book Built Issue IPO |
Listing At | BSE, NSE |
Official Website | https://www.global-health.com/ |
Presently, Sachdeva and Anant Investments both possess 13.41% of Global Health, while Anant Investments controls 25.64% of the business. The proceeds of the new issue will be used for general corporate activities and debt reduction.
Global Health Limited IPO GMP Tentative Timetable
Event | Tentative Date |
Opening Date | November 3, 2022 |
Closing Date | November 7, 2022 |
Basis of Allotment | November 11, 2022 |
Initiation of Refunds | November 14, 2022 |
Credit of Shares to Demat | November 15, 2022 |
Listing Date | November 16, 2022 |
About Global Health
Global Health is a premier private multi-specialty tertiary care provider in the North and East of India. It was established by renowned cardiovascular and cardiothoracic surgeon Naresh Trehan.
Global Health operates a network of five hospitals under the Medanta name in Gurugram, Indore, Ranchi, Lucknow, and Patna with the help of private equity partners such as the Carlyle Group and Temasek. Furthermore, Noida is building one hospital.
Cardiology and cardiac science, neurosciences, cancer, digestive and hepatobiliary sciences, orthopaedics, liver transplant, renal and urology are among the company’s major specialties.
The company reported total revenues of Rs 2,205.8 crore and profits of Rs 196.2 crore in FY22. The business also plans to benefit from medical tourism as part of its growth goals.
Global Health Competitive Strengths
- Leading supplier of tertiary and quaternary care in India, highly known for its clinical proficiency, particularly in handling challenging situations.
- Concentrate on academics and clinical research.
- large hospitals with top-notch facilities, modern medical technology, and equipment.
- Strong operational and financial performance history.
- Concentrate on underserved areas with high population densities, and be present in the largest or capital cities of big states (NCR, Lucknow and Patna).
- Possibilities for expansion in already-built facilities and diversification into new services, like digital health.
- A senior management team with extensive experience and significant institutional shareholder support.
Global Health Financial Performance (in Cr.)
FY 2020 | FY 2021 | FY 2022 | Q1 FY 2023 | |
Revenue | 1,500.4 | 1,446.7 | 2,166.6 | 617.2 |
Expenses | 1,480.4 | 1,445.7 | 1,925.3 | 539.5 |
Net income | 36.3 | 28.8 | 196.2 | 58.7 |
Margin (%) | 2.42 | 1.99 | 9.06 | 9.51 |
The object of the Issue
- investment in two of the subsidiaries, GHPPL and MHPL, in order to prepay or repay all of the borrowings made by those subsidiaries.
- broader corporate objectives.
Global Health IPO GMP Market Lot
Minimum Lot Size | TBA |
Minimum Share | TBA |
Minimum Amount | TBA |
Maximum Lot Size | TBA |
Maximum shares | TBA |
Maximum Amount | TBA |
The company reported total revenues of Rs 2,205.8 crore and profits of Rs 196.2 crore in FY22. According to a Crisil research, the Indian healthcare delivery sector is anticipated to register a 13–15% CAGR between FY21 and FY26, driven by penned-up demand, solid fundamentals, rising affordability, and the Ayushman Bharat Yojana.
In addition, the county has a bed density of only 15 beds per 10,000 people, which is lower than the global median of 29 beds. The book running lead managers for the IPO are JM Financial, Credit Suisse Securities (India), Jefferies India, and Kotak Mahindra Capital Company.
Please address any questions you may have in the comments area below regarding Global Health Limited IPO GMP.
Official Website | Click Here |
Homepage | jkdsd.org |